ReWalk Robotics (NSDQ:RWLK) said today it inked a collaborative research with Harvard’s Wyss Institute to develop a lightweight “soft suit” exoskeleton system for lower limb disabilities. The collaboration looks to design a suit to treat stroke, multiple sclerosis and mobility limitations for the elderly as well as other applications. Through the agreement, ReWalk will pay Harvard […]
Harvard University
New from the biotech store: an improved gene editing tool
(Reuters) – Scientists have developed an improved gene editing tool that significantly reduces potentially dangerous “off-target” edits, promising an even more precise and efficient system for manipulating human DNA. Editing the genes of living organisms, including humans, holds out great promise for treating diseases. But it could also be used to create “designer babies”, prompting […]
Baxter gets in on Harvard spun-out Opsonix
New Harvard spin-out blood pathogen-extracting device developer Opsonix said it raised $8 million in its Series A round upon launching, led by Baxter (NYSE:BAX) Ventures. Opsonix is developing a device to remove infectious pathogens and toxins from circulating blood, to treat blood-borne infectious diseases,including sepsis, the Cambridge, Mass.-based company said. “Opsonix’s pathogen-extracting therapy provides a novel […]
OSP fishes up $11m | Medtech funding for the week of March 23, 2015
Diabetes: Medtronic joins $44m round for Semma Therapeutics
Downtime in 2002 versus 2013
On November 13, 2002, the network core at Beth Israel Deaconess failed due to a complex series of events and the hospital lost access to all applications.
Dr. Jonathan Gruber: Can we control costs in healthcare reform?
Harvard Law School rounded up a panel of experts to discuss some of the implications of healthcare reform in the 1st annual Health Law in Review panel discussion.
New heart valves have a steep learning curve | MassDevice.com On Call
MASSDEVICE ON CALL — Major complications occur frequently in patients undergoing transcatheter aortic valve implantation procedures, according to an analysis of data from the Edwards Lifesciences (NYSE:EW) Partner TAVI trial published in Interventional Surgery.